13 results on '"Wakui, Hiroshi"'
Search Results
2. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
- Author
-
Utsumi, Hirofumi, Araya, Jun, Okuda, Keitaro, Watanabe, Junko, Takekoshi, Daisuke, Fujita, Yu, Hashimoto, Mitsuo, Wakui, Hiroshi, Minagawa, Shunsuke, Numata, Takanori, Hara, Hiromichi, and Kuwano, Kazuyoshi
- Subjects
IMMUNE checkpoint inhibitors ,PNEUMONIA ,NON-small-cell lung carcinoma ,RESPIRATORY insufficiency ,INTENSIVE care units - Abstract
Immune checkpoint inhibitor (ICI)-related pneumonitis is a relatively rare but clinically serious and potentially life-threatening adverse event. The majority of cases can be managed by drug discontinuation, with the administration of corticosteroids added in severe cases. However, worsening of pneumonitis can develop in a subset of patients despite treatment with high doses of corticosteroids. We herein report a case of steroid-refractory ICI-related pneumonitis in a recurrent non-small cell lung cancer (NSCLC) patient treated with pembrolizumab that was successfully improved by triple combination therapy (high-dose corticosteroids, tacrolimus, and cyclophosphamide). After 3 weeks of initial pembrolizumab administration, the patient was diagnosed with ICI-related pneumonitis. Chest computed tomography (CT) showed patchy distributed bilateral consolidation and ground-glass opacities (GGOs) with traction bronchiectasis and bronchiolectasis resembling the diffuse alveolar damage (DAD) radiographic pattern. Although methylprednisolone pulse therapy was initiated, worsening of respiratory failure resulted in the patient being transferred to the intensive care unit. Because of an insufficient therapeutic response to high-dose corticosteroids, tacrolimus and cyclophosphamide pulse therapy were additively performed as triple combination therapy according to the treatment strategy for pulmonary complications of clinically amyopathic dermatomyositis (CADM). In response to this triple combination therapy, the patient's respiratory condition gradually improved, and chest CT showed the marked amelioration of pulmonary opacities. This is the first report suggesting the efficacy of triple combination therapy (high-dose corticosteroids, tacrolimus, and cyclophosphamide) for steroid-refractory ICI-related pneumonitis complicated with respiratory failure. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Finite time blow up and non-uniform bound for solutions to a degenerate drift-diffusion equation with the mass critical exponent under non-weight condition.
- Author
-
Ogawa, Takayoshi and Wakui, Hiroshi
- Abstract
We consider the non-existence and the non-uniform boundedness of a time global solution to the Cauchy problem of a degenerate drift-diffusion system with the mass critical exponent. If the initial data has negative free energy, then either the corresponding weak solution to the equation does not exist globally in time, or the time global solution does not remain bounded in the energy space. We emphasize that our result does not require any weight assumption on the initial data, and hence, a solution may have an infinite second moment. The proof is based upon the modified virial law and conservation laws and we show that the modified moment functional vanishes for a finite time under the negative energy condition. For a radially symmetric case, the solution blows up in finite time and the mass concentration phenomenon occurs with a sharp lower bound related to the best constant for the Hardy–Littlewood–Sobolev inequality. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. The rate of concentration for the radially symmetric solution to a degenerate drift-diffusion equation with the mass critical exponent.
- Author
-
Wakui, Hiroshi
- Abstract
We consider the concentration rate of the total mass for radially symmetric blow-up solutions to the Cauchy problem of a degenerate drift-diffusion system with the mass critical exponent. We proved that the radially symmetric solution blows up in finite time when the initial data has negative free energy. We show that the mass concentration phenomenon occurs with the sharp lower constant related to the best constant of the Hardy-Littlewood-Sobolev inequality and the concentration rate of the total mass. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.
- Author
-
Yamamoto, Noboru, Nokihara, Hiroshi, Yamada, Yasuhide, Shibata, Takashi, Tamura, Yosuke, Seki, Yoshitaka, Honda, Kazunori, Tanabe, Yuko, Wakui, Hiroshi, and Tamura, Tomohide
- Subjects
CLINICAL trials ,DRUG dosage ,DRUG toxicity ,IMMUNOGLOBULINS ,IMMUNOTHERAPY ,LIFE expectancy ,TUMORS ,DISEASE progression ,LYMPHOPENIA ,DESCRIPTIVE statistics - Abstract
Background This study evaluated the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of single and multiple doses of nivolumab in Japanese patients with malignant solid tumors. Subjects and Methods This was an open-label, dose-escalation study in 17 patients with advanced solid tumors with a life expectancy of ≥3 months. Patients were observed for 3 weeks after a single dose of nivolumab at 1, 3, 10 or 20 mg/kg, then received the same dose of nivolumab every 2 weeks until unacceptable toxicity or disease progression occurred. This study included a maximum dose of 20 mg/kg, which is the highest dose of nivolumab evaluated to date. The maximum dose was 10 mg/kg in previous studies. Results The commonest adverse drug reaction was lymphopenia, which occurred in 10 (58.8%) patients, including two (11.8%) with Grade ≥3 events. No dose-limiting toxicities (DLTs) were observed up to the maximum dose of 20 mg/kg. The area under the concentration-time curve from time 0 to the last measurable concentration was linear up to 20 mg/kg. The maximum concentration showed dose-dependency up to 10 mg/kg, but not between 10 and 20 mg/kg. One durable complete response and two partial responses were observed. Conclusions Nivolumab at doses of 1-20 mg/kg was not associated with DLTs, and it was generally well tolerated at doses of up to 20 mg/kg in Japanese patients with advanced solid tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.
- Author
-
Nokihara, Hiroshi, Yamada, Yasuhide, Fujiwara, Yutaka, Yamamoto, Noboru, Wakui, Hiroshi, Nakamichi, Shinji, Kitazono, Satoru, Inoue, Kohei, Harada, Akiko, Taube, Tillmann, Takeuchi, Yoshito, and Tamura, Tomohide
- Published
- 2016
- Full Text
- View/download PDF
7. A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.
- Author
-
Nakamichi, Shinji, Nokihara, Hiroshi, Yamamoto, Noboru, Yamada, Yasuhide, Honda, Kazunori, Tamura, Yosuke, Wakui, Hiroshi, Sasaki, Tatsuya, Yusa, Wataru, Fujino, Katsuki, and Tamura, Tomohide
- Subjects
PROTEIN-tyrosine kinase inhibitors ,JAPANESE people ,PHARMACOKINETICS ,MEDICATION safety ,ORAL drug administration ,DISEASES ,ASIANS ,BIOTRANSFORMATION (Metabolism) ,CLINICAL trials ,COMPARATIVE studies ,HEADACHE ,RESEARCH methodology ,MEDICAL cooperation ,NAUSEA ,QUINOLINE ,RESEARCH ,THROMBOCYTOPENIA ,TUMORS ,UREA ,EVALUATION research ,TREATMENT effectiveness ,PROTEIN kinase inhibitors - Abstract
Purpose: This phase 1 study aimed to assess the tolerability, safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of lenvatinib capsules in Japanese patients with solid tumors when administered orally up to 24 mg on a once-daily (QD) continuous schedule.Methods: Patients were enrolled in one of the two sequential cohorts (20 or 24 mg) of lenvatinib on a 28-day cycle based on the conventional 3 + 3 dose escalation design. Adverse events (AEs) were graded using the Common Terminology Criteria for Adverse Events, version 4.0. Tolerability was judged based on dose-limiting toxicities (DLTs) during Cycle 1. The drug was defined as tolerable when the incidence of DLTs was less than 33 %.Results: Nine patients received lenvatinib [20 mg (n = 3); 24 mg (n = 6)]. No DLTs were observed. The most common AEs were thrombocytopenia, blood thyroid stimulating hormone increased, and hypertension (89 %), followed by leukopenia, headache, and proteinuria (78 %). The area under the concentration-time curve and maximum observed concentration increased dose proportionally. The PK profiles were similar to those in non-Japanese phase 1 studies. One patient with leiomyosarcoma showed a partial response, and three patients have maintained stable disease for more than 6 months.Conclusions: The 24-mg QD continuous dose of lenvatinib was determined to be tolerable with encouraging anti-tumor activity in Japanese patients with solid tumors. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
8. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.
- Author
-
Horinouchi, Hidehito, Yamamoto, Noboru, Fujiwara, Yutaka, Sekine, Ikuo, Nokihara, Hiroshi, Kubota, Kaoru, Kanda, Shintaro, Yagishita, Shigehiro, Wakui, Hiroshi, Kitazono, Satoru, Mizugaki, Hidenori, Tokudome, Takuto, and Tamura, Tomohide
- Subjects
ANTINEOPLASTIC agents ,ACADEMIC medical centers ,COMBINATION drug therapy ,DOSE-response relationship in biochemistry ,DRUG side effects ,LUNG cancer ,PACLITAXEL ,PHARMACOKINETICS ,RESEARCH funding ,SAFETY ,TREATMENT effectiveness ,IPILIMUMAB ,DESCRIPTIVE statistics ,CARBOPLATIN ,PHARMACODYNAMICS ,THERAPEUTICS - Abstract
Background Ipilimumab is an antibody that targets the cytotoxic T-lymphocyte antigen-4 to potentiate an antitumor response. Adding ipilimumab 10 mg/kg to paclitaxel (PTX) and carboplatin (CBDCA) in a phased schedule improved progression-free survival in a phase II non-small-cell lung cancer (NSCLC) study. Methods This dose-escalating, phase I study was designed to identify the recommended dose of ipilimumab (3 or 10 mg/kg) by evaluating dose-limiting toxicity (DLT; Cycles 3 and 4) in phased combination with PTX (175 mg/m) and CBDCA (area under the curve = 6) in Japanese patients with advanced NSCLC. Treatment was administered intravenously every 3 weeks initially, followed by some eligible patients receiving maintenance ipilimumab once every 12 weeks. Additional endpoints included safety, tumor response, pharmacokinetics, and immunogenicity. Results Fifteen patients were enrolled and 12 received ipilimumab ( n = 6, 3 mg/kg; n = 6, 10 mg/kg) in combination with PTX and CBDCA. DLTs occurred in 2 patients (ipilimumab 3 mg/kg) and 1 patient (ipilimumab 10 mg/kg). The most common grade 3/4 adverse events (AEs) were decreased hemoglobin, leukopenia, and neutropenia. The most common immune-related AEs affected the skin, gastrointestinal, and nervous system. The safety profile was similar in both cohorts. Three patients in each cohort achieved a partial response. The pharmacokinetic (PK) profile of ipilimumab in Japanese patients was similar to that observed in previous studies in non-Japanese patients. Conclusions The recommended dose of ipilimumab in phased combination with PTX and CBDCA in Japanese patients with NSCLC was identified as 10 mg/kg. The safety profile was consistent with the previously defined AE profile. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
- Author
-
Nakamichi, Shinji, Nokihara, Hiroshi, Yamamoto, Noboru, Yamada, Yasuhide, Fujiwara, Yutaka, Tamura, Yosuke, Wakui, Hiroshi, Honda, Kazunori, Mizugaki, Hidenori, Kitazono, Satoru, Tanabe, Yuko, Asahina, Hajime, Yamazaki, Naoya, Suzuki, Shigenobu, Matsuoka, Mieko, Ogita, Yoshitaka, and Tamura, Tomohide
- Subjects
THERAPEUTIC use of biochemical markers ,ACADEMIC medical centers ,ANTINEOPLASTIC agents ,BLOOD testing ,CLINICAL trials ,DOSE-effect relationship in pharmacology ,GENETIC mutation ,RESEARCH funding ,DATA analysis software ,DESCRIPTIVE statistics ,PHARMACODYNAMICS - Abstract
RO4987655 is an oral and selective inhibitor of MEK, a key enzyme of the mitogen-activated protein kinase (MAPK) signaling pathway. This phase I dose-escalation study of RO4987655 in Japanese patients with advanced solid tumors aimed to determine maximum tolerated dose (MTD) and to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity. Patients received a single dose of RO4987655 (1, 2, 4, 5, or 6.5 mg) followed by continuous once-daily dosing (1, 2, or 4 mg QD) or twice-daily dosing (4, 5, or 6.5 mg BID) in 28-day cycles. A 3 + 3 dose-escalation design was used. PD was evaluated by pERK inhibition in peripheral blood mononuclear cells (PBMCs). In dose-escalation, 25 patients were enrolled. After the MTD was determined, a further six patients were administered the MTD for further confirmation of safety. MTD was determined as 8 mg/day (4 mg BID) due to a total of four dose-limiting toxicities (DLTs) of grade 3 creatine phosphokinase (CPK) elevation (2 DLTs each in 10 mg/day and 13 mg/day). Most commonly related adverse events included dermatitis acneiform, CPK elevation, and eye disorders. Plasma concentration of RO4987655 appeared to increase in a dose-proportional manner with a plasma half-life of 4.32 to 21.1 h. Following multiple dose administration, a steady-state condition was reached by Cycle 1 Day 8. The inhibitory effects of RO4987655 on pERK in PBMCs increased in a dose-dependent manner. One esophageal cancer patient had confirmed partial response and seven patients showed progression-free survival for longer than 16 weeks. The MTD of RO4987655 for Japanese patients was determined as 8 mg/day (4 mg BID). RO4987655 was tolerated up to the MTD with a favorable PK/PD profile in Japanese patients with advanced solid tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.
- Author
-
Nishio, Makoto, Horiike, Atsushi, Nokihara, Hiroshi, Horinouchi, Hidehito, Nakamichi, Shinji, Wakui, Hiroshi, Ohyanagi, Fumiyoshi, Kudo, Keita, Yanagitani, Noriko, Takahashi, Shunji, Kuboki, Yasutoshi, Yamamoto, Noboru, Yamada, Yasuhide, Abe, Masaichi, Tahata, Takashi, and Tamura, Tomohide
- Subjects
ANTINEOPLASTIC agents ,ACADEMIC medical centers ,CLINICAL trials ,DOSE-effect relationship in pharmacology ,LUNG tumors ,MEDICAL cooperation ,MONOCLONAL antibodies ,PHARMACOKINETICS ,RESEARCH ,RESEARCH funding ,SAFETY ,DESCRIPTIVE statistics - Abstract
Onartuzumab is a monovalent, humanized, monoclonal antibody that showed significant survival benefits in combination with erlotinib in MET-positive non-small-cell lung cancer (NSCLC) in pre-specified subgroup analyses of a randomized phase II study. We conducted a two-stage, open-label, multicenter, phase I study of onartuzumab in Japanese patients. Stage 1 investigated the safety, tolerability, pharmacokinetics (PK), and recommended dose of onartuzumab in patients with solid tumors, and Stage 2 determined the safety, tolerability, and PK of onartuzumab plus erlotinib in patients with MET-positive NSCLC. Nine patients received onartuzumab monotherapy (4, 15, or 30 mg/kg on Day 1 of each 21-day cycle) in Stage 1, and six patients received onartuzumab (15 mg/kg) plus erlotinib (150 mg/day) in Stage 2. There were no dose-limiting toxicities in either stage. Serious adverse events (AEs) occurred in one patient in Stage 1 (convulsion), and two patients in Stage 2 (once case each of diarrhea, vomiting, and pulmonary embolism), but there were no grade 4 AEs or AEs leading to death. Onartuzumab PKs were linear in the dose range of 4 to 30 mg/kg, and were not affected by co-administration with erlotinib. PK parameters of onartuzumab were similar to those reported in non-Japanese patients. A partial response was observed in a patient with MET immunohistochemistry 3+ NSCLC without MET gene amplification. Based on these results, the recommended dose of onartuzumab in Japanese patients with solid tumors is 15 mg/kg every 21 days. The combination of onartuzumab with erlotinib is feasible in Japanese patients with MET-positive lung cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors.
- Author
-
Wakui, Hiroshi, Yamamoto, Noboru, Kitazono, Satoru, Mizugaki, Hidenori, Nakamichi, Shinji, Fujiwara, Yutaka, Nokihara, Hiroshi, Yamada, Yasuhide, Suzuki, Kohei, Kanda, Hironori, Akinaga, Shiro, and Tamura, Tomohide
- Subjects
- *
DRUG dosage , *JAPANESE people , *KINESIN , *GRANULOCYTE-macrophage colony-stimulating factor , *NEUTROPENIA , *TREATMENT effectiveness , *DISEASES ,TUMOR prevention - Abstract
Purpose: Eg5, a mitotic motor kinesin protein, plays an essential role in bipolar spindle formation in the M phase of the cell cycle. LY2523355 (litronesib) is an allosteric inhibitor of Eg5. This phase 1 and dose-finding study aimed to assess the safety, pharmacokinetics (PK), recommended dose for further studies, and preliminary efficacy in Japanese patients with advanced solid tumors. Methods: LY2523355 was given on days 1, 2, and 3 every 3 weeks at one of three dose levels: 2, 4, and 5 mg/m/day. Toxicity was assessed according to NCI-CTCAE version 4.0, and tumor response according to RECIST version 1.1. granulocyte colony-stimulating factor (G-CSF) was used only for grade 4 neutropenia or grade 3 febrile neutropenia. Results: Twelve patients were treated at doses of 2 ( n = 3), 4 ( n = 3), and 5 ( n = 6) mg/m/day. Most frequent treatment-related adverse events were neutropenia and leukopenia (100 %). Grade 4 neutropenia was observed in 83 %, but all recovered to above 500 neutrophils/μl within 7 days. All patients at 4 and 5 mg/m/day required G-CSF support. No dose-limiting toxicities were reported up to 5 mg/m/day. In PK analysis, LY2523355 exposure increased in a dose-dependent manner. The PK parameters for LY2523355 were similar to those observed in Western populations. No objective tumor responses were observed. Conclusions: The recommended dose of LY2523355 with therapeutic G-CSF use for further studies was determined to be 5 mg/m/day in Japanese patients with advanced solid tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.
- Author
-
Wakui, Hiroshi, Yamamoto, Noboru, Nakamichi, Shinji, Tamura, Yousuke, Nokihara, Hiroshi, Yamada, Yasuhide, and Tamura, Tomohide
- Subjects
- *
IMMUNOMODULATORS , *MONOCLONAL antibodies , *EPIDERMAL growth factor receptors , *PROTEIN-tyrosine kinases , *PHARMACOKINETICS , *BIOMARKERS , *DISEASE progression - Abstract
Purpose: Patritumab (U3-1287) is a human epidermal growth factor receptor-3 (HER3)-targeted antibody that blocks ligand-associated activation of HER3. This open-label, phase 1 and dose-finding study (ClinicalTrials.jp Identifier: JapicCTI-101262) aimed to assess the safety, pharmacokinetics, incidence of anti-patritumab antibody, recommended dose for subsequent clinical studies, preliminary efficacy, and patritumab-related biomarkers in Japanese patients with advanced solid tumors. Methods: Patients received patritumab 9 or 18 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity occurred. Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0). Dose-limiting toxicities (DLTs) were evaluated from the initial dose to Cycle 1 Day 21. Tumor response was assessed with Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). Results: Nine patients received patritumab 9 mg/kg ( n = 3) or 18 mg/kg ( n = 6). Five patients were male, all patients had Eastern Cooperative Oncology Group performance status (PS) ≤ 1, and median (range) age of 67 (50-69) years. No DLTs were reported. Patritumab-related AEs reported in ≥2 patients were ALT increase (three patients), thrombocytopenia, diarrhea, stomatitis, cheilitis, rash maculo-papular and AST increase (two each). Pharmacokinetics profile was similar to the preceding US phase 1 study. Soluble HER3 concentration in serum unexpectedly increased in all patients. These changes did not correlate with clinical response. Four patients had a best response of stable disease. All patients tested had negative for anti-patritumab antibody formation. Conclusions: Patritumab was well tolerated up to 18 mg/kg without DLTs in Japanese patients with advanced solid tumors. Soluble HER3 increased in all patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis.
- Author
-
Yoshida, Masahiro, Minagawa, Shunsuke, Araya, Jun, Sakamoto, Taro, Hara, Hiromichi, Tsubouchi, Kazuya, Hosaka, Yusuke, Ichikawa, Akihiro, Saito, Nayuta, Kadota, Tsukasa, Sato, Nahoko, Kurita, Yusuke, Kobayashi, Kenji, Ito, Saburo, Utsumi, Hirohumi, Wakui, Hiroshi, Numata, Takanori, Kaneko, Yumi, Mori, Shohei, and Asano, Hisatoshi
- Abstract
Ferroptosis is a necrotic form of regulated cell death (RCD) mediated by phospholipid peroxidation in association with free iron-mediated Fenton reactions. Disrupted iron homeostasis resulting in excessive oxidative stress has been implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD). Here, we demonstrate the involvement of ferroptosis in COPD pathogenesis. Our in vivo and in vitro models show labile iron accumulation and enhanced lipid peroxidation with concomitant non-apoptotic cell death during cigarette smoke (CS) exposure, which are negatively regulated by GPx4 activity. Treatment with deferoxamine and ferrostatin-1, in addition to GPx4 knockdown, illuminate the role of ferroptosis in CS-treated lung epithelial cells. NCOA4-mediated ferritin selective autophagy (ferritinophagy) is initiated during ferritin degradation in response to CS treatment. CS exposure models, using both GPx4-deficient and overexpressing mice, clarify the pivotal role of GPx4-regulated cell death during COPD. These findings support a role for cigarette smoke-induced ferroptosis in the pathogenesis of COPD. Altered iron homeostasis resulting in excessive oxidative stress has been implicated in smoke-induced lung diseases. Here the authors show that ferroptosis of lung epithelial cells, potentially resulting from excessive ferritinophagy, is involved in the pathogenesis of COPD. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.